Champions Oncology, Inc. · NASDAQ:CSBR
Champions Oncology — Investor Presentation (January 2013)
32 slides from Champions Oncology's investor presentation, Jan 7, 2013
Slide 1: A proprietary in vivo testing and information platform for personalizing cancer care
A proprietary in vivo testing and information platform for personalizing cancer care January 2013
Slide 2: Notice of Forward Looking Statements
Notice of Forward Looking Statements This presentation contains certain “forward - looking statements,” which include information relating to future events, future financial performance, strategies, expectations, competitive environment, regulation, and availability of resources . These forward - lo
Slide 3: Company Overview
Diversified business model C ombines advantages of technology and service business Company Overview Experienced leadership team Diverse experience with shareholder focus Proprietary approach to personalized oncology Predictive technology serving patients and drug development companies
Slide 4: Living bank of tumors and diagnostic business strategy
Build living bank of tumors with patient specific clinical, genomic and response data. Leverage technology, tumors and information to generate technology revenue and IP. Build patient diagnostic business utilizing TumorGraft technology 2 X + 7 Z + 3 A + 16 D + 2 E + 4 F + 1 G + 0 Y + 3 Z + 56 A + 2
Slide 5: Fundamental Problem of Oncology: Most Drugs Don't Work For Most Patients
Fundamental Problem of Oncology: Most Drugs Don’t Work For Most Patients Source: Spear et al TRENDS in molecular Medicine Vol. 7 No. 5 May 2001 ; PMC Nov 2006 , Life Technologies 0 10 20 30 40 50 60 Response Rates (%) Analgesics Statins Depression (SSRI) Schizophrenia Cardiac Arrythmias Asthma Diabe
Slide 6: The Complexity of Cancer
The Complexity of Cancer The genetic, germline and epigenetic heterogeneity of cancer, within each patient and across the a population of patients, has limited the efficacy of modeling cancer in vivo . 1 New Engl J Med 2012 ; 366 : 883 - 892 March 8 , 2012 2 LabMed June 2010 vol. 41 no. 6 364 - 37
Slide 7: Champions TumorGrafts are Superior to Cell Line Xenografts
Champions TumorGrafts are Superior to Cell Line Xenografts Champions TumorGrafts maintain the heterogeneity and preserve the microenvironment that supports the tumor growth. Limited number of passes used to preserve human characteristics of tumors .
Slide 8: Histological Similarity to Human Tumors
Histological Similarity to Human Tumors 8 TumorGraft sample shows similar histological heterogeneity and complexity as human tumor. Cell line xenograft sample has been dedifferentiated to a homogenous and unrepresentative mass. H&E Stain of Colon Cancer Samples Human Tumor TumorGraft Cell Line Xenog
Slide 9: Published Results Demonstrate Predictive Accuracy
Published Results Demonstrate Predictive Accuracy 1 A Pilot Clinical Study of Treatment Guided by Personalized Tumorgrafts in Patients with Advanced Cancer Hidalgo, et al . Molecular Cancer Therapeutics 2011 ; 10 : 1311 - 1316 “The objective response rate was 88 % for treatments deemed effective b
Slide 10: Comparable Predictive Results have been Observed in our Patient Studies
10 Comparable Predictive Results have been Observed in our Patient Studies 63 Patient Drug Studies 1 7 Predictions of Resistance 6 56 Predictions of Sensitivity 52 4 10 False Negatives True Negatives True Positives False Positives Champions TumorGraft platform has accurately predicted sensitivity an
Slide 11: Personalized TumorGraft: Product Overview
Personalized TumorGraft : Product Overview Process Tumor fragments implanted directly into group of 5 - 10 mice 2 Implant Groups of mice are dosed with compounds chosen for testing 4 Testing Tumor growth inhibition results delivered to oncologist 5 Results Colony of mice is expanded based on patient
Slide 12: Personalized TumorGraft - Pancreatic Case Study
Villarroel et al. Mol Cancer Ther , 2011 : 10 : 3 - 8 . Personalized TumorGraft - Pancreatic Case Study TumorGraft sensitive to Mitomycin C and Cisplatin . TumorGraft ™ Insights : Mitomycin C response maintained for 22 months. Patient remains asymptomatic as of last follow - up ( 5 years post - rese
Slide 13: Personalized TumorGraft Commercialization: Current Status
Personalized TumorGraft Commercialization: Current Status Product Detail: • Available for most solid tumors • Used for second line therapy or later Sales and Marketing Efforts • Active sales and marketing efforts in US and UK • Expanding into SE Asia this quarter • Increasing sampling effort to i
Slide 14: Three Pronged Approach to Clinical Validation
Three Pronged Approach to Clinical Validation Champions is leveraging the existing patient base and academic interest to enhance clinical validation in a cost effective manner. Publications • Growing base of study results from individual patients • Aggregating by tumor type for publication Pilot
Slide 15: X+ B + C + D + E + F + G + H
2 X+ 0 B + 3 C + 4 D + 1 E + 2 F + 1 G + 11 H + 41 I + 3 J 0 X + 2 Y + 4 Z + 1 A + 25 B + 5 C + 21 D + 6 E + 2 F + 2 G + 3 H + 7 I + 11 J 13 X + 1 Y + 8 Z + 2 A + 7 B + 2 C + 3 D + 5 E + 1 F + 1 G + 6 H + 26 I + 14 Y + 7 Z + 3 A + 5 B + 0 C + 16 D + 2 E + 4 F + 1 G + 9 H + 0 I + 23 J 13 X + 0 Y + 3
Slide 16: Our Models: Cheaper Humans or Better Mice
Our Models: Cheaper Humans or Better Mice Moderate Response Champions TumorGraft Testing TumorGraft technology is used to match individual patients with specific drugs to increase the response rates to oncology drugs. Respond Only in Combination Robust Response Not Likely to Respond
Slide 17: An Emerging Paradigm of Oncology Drug Development
An Emerging Paradigm of Oncology Drug Development TumorGraft technology combined with a Living TumorBank enables drug developers to answer the key questions of drug development without the expense and constraints of human clinical trials. Study Type Questions Answered Efficacy: Does this compound
Slide 18: Translational Oncology Solutions: Case Study
Translational Oncology Solutions: Case Study 18 Situation Overview Oncology compound in phase 1 clinical trial. Broad mechanism of action. Interest in multiple tumor types. Study Objective Determine response rates across multiple tumor types to pick one for phase II trial. Study Design Measure tumor
Slide 19: TOS Case Study: Study Results
19 19 TOS Case Study: Study Results Colon NSCLC Pancreatic Tumor Type Response Rate* Colon 67 % NSCLC 33 % Pancreatic 33 % TumorGraft study demonstrated significantly higher response rate in colon cancer. Bioinformatic study was initiated to begin patient enrichment strategy.
Slide 20: Utilization of Tumorgraft Technology is Accelerating Rapidly
Utilization of Tumorgraft Technology is Accelerating Rapidly 20 1 Publications using the search term patient derived xenografts 0 200 400 600 800 1000 1200 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 Pub licati ons per Year 1 Recognition of the value of TumorGrafts is growing. Scale and divers
Slide 21: A Differentiated Strategy for the Future
A Differentiated Strategy for the Future Clinical Translational Pre - Clinical Champions strategy is to develop TumorGraft offerings focused on products in the clinical phase of development. Advantages of Clinical Stage: • Bigger budgets • Higher value • Differentiated offering • Less competition
Slide 22: Growing Utilization of TumorGrafts by Pharma Companies
Growing Utilization of TumorGrafts by Pharma Companies Most of the largest oncology drug development companies have utilized Champions’ translational oncology solutions. Annual Revenue from Translational Oncology Solutions ($ ‘ 000 ) - 1,000 2,000 3,000 4,000 5,000 6,000 F2009 F2010 F2011 F2012 I
Slide 23: An Emerging Consensus on Biomarkers in Oncology
An Emerging Consensus on Biomarkers in Oncology “Biomarkers are central to accelerating the identification and adoption of new therapies” AACR - FDA - NCI Cancer Biomarkers Collaborative Consensus Report
Slide 24: Champions Offers a Unique Platform for Biomarker Development
Champions Offers a Unique Platform for Biomarker Development Challenges of Biomarker Discovery • Small patient populations available for study • Studies limited to drugs or combinations used by patients • Limited availability of tumor tissue for analysis • Must repeat molecular analysis every stu
Slide 25: A New Tool; Not a New Methodology
A New Tool; Not a New Methodology Utilization of in vivo models for biomarker discovery has been used in the past with limited success. The accuracy and scale of our platform will enhance the power of the methodology. Systematic identification of genomic markers of drug sensitivity in cancer cell
Slide 26: Success in Biomarker Discovery
Success in Biomarker Discovery Response to AZ 0560 in 16 pancreatic TumorGrafts • 3 of 16 demonstrated a response indicative of sensitivity (A) • LRRC 19 and IGFBP 2 identified • Demonstrated 87.5 % accuracy in test set (B) 26 A B Mig 6 in Tarceva Pivotal Phase II in Lung CA 0 20 40 60 80 100 0 2 4
Slide 27: Strategic Approach to Biomarker Development
Strategic Approach to Biomarker Development • Focus on discovery and clinical validation phases Focus • Partnerships that provide added value at all stages of process Partner • Diversification to provide multiple “shots on goal” Diversify Our biomarker development strategy will mitigate the scien
Slide 28: Future Milestones
Future Milestones Building out senior management team First biomarker out licensing deal Insurance reimbursement First biomarker partnership agreement First “mouse phase II clinical trial” Initiation of clinical validation studies Increased implantations and studies Peer reviewed publications Con
Slide 29: A Deep and Experienced Senior Management Team
A Deep and Experienced Senior Management Team Dr. David Sidransky – Chairman of the Board • Former Vice Chairman, ImClone Systems • Professor of Oncology, Otolaryngology, Cellular and Molecular Medicine, Urology, Genetics, and Pathology at Johns Hopkins Joel Ackerman – Chief Executive Officer • 1
Slide 30: Annual Results
$000's FY 2012 FY 2011 OPERATIONAL STATS New POS Implants 94 12 POS Studies 19 5 OPERATING REVENUE: TOS 4,817$ 3,500$ POS 2,332 3,382 Total operating revenue 7,149$ 6,882$ COSTS and OPERATING EXPENSE: Cost of TOS 2,533$ 1,806$ Cost of POS 2,331 1,806 Research and development 2,898$ 2,809$ Sales and
Slide 31: Financial Information
Financial Information 1 Ticker Symbol (OTC): CSBR Cash balance: $ 2.5 million Shares outstanding: 47 million shares S tock price: $ 0.30 52 week range: $ 0.21 - $ 0.75 Market Capitalization: $ 14.1 million 1 Financial information as of January 4 , 2013 .
Slide 32: Summary of Key Investment Highlights
Summary of Key Investment Highlights Differentiated technology with multiple applications serving large markets with unmet needs Business model that combines benefits of technology and service businesses Revenue stream demonstrates commercial viability of products Near term milestones to measure
Champions Oncology — Investor Presentation (January 2013) on 6ix